MX2020012331A - TRATAMIENTO DE FIBROSIS PULMONAR IDIOPÁTICA CON INHIBIDORES DE GLUCÓGENO-SINTASA-CINASA 3 FORMA ß. - Google Patents
TRATAMIENTO DE FIBROSIS PULMONAR IDIOPÁTICA CON INHIBIDORES DE GLUCÓGENO-SINTASA-CINASA 3 FORMA ß.Info
- Publication number
- MX2020012331A MX2020012331A MX2020012331A MX2020012331A MX2020012331A MX 2020012331 A MX2020012331 A MX 2020012331A MX 2020012331 A MX2020012331 A MX 2020012331A MX 2020012331 A MX2020012331 A MX 2020012331A MX 2020012331 A MX2020012331 A MX 2020012331A
- Authority
- MX
- Mexico
- Prior art keywords
- glycogen synthase
- synthase kinase
- treatment
- ing
- pulmonary fibrosis
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000001267 GSK3 Human genes 0.000 title abstract 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 title 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 title 1
- FARXPFGGGGLENU-UHFFFAOYSA-N 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Chemical compound C12=CC=3OCOC=3C=C2N(C)C=C1C1=C(C=2C3=CC(F)=CC=C3OC=2)C(=O)NC1=O FARXPFGGGGLENU-UHFFFAOYSA-N 0.000 abstract 3
- 230000003176 fibrotic effect Effects 0.000 abstract 3
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000002685 pulmonary effect Effects 0.000 abstract 2
- 238000007634 remodeling Methods 0.000 abstract 2
- 238000012338 Therapeutic targeting Methods 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 101150090422 gsk-3 gene Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 210000000651 myofibroblast Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672864P | 2018-05-17 | 2018-05-17 | |
| PCT/US2019/032639 WO2019222483A1 (en) | 2018-05-17 | 2019-05-16 | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012331A true MX2020012331A (es) | 2021-03-09 |
Family
ID=68541026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012331A MX2020012331A (es) | 2018-05-17 | 2019-05-16 | TRATAMIENTO DE FIBROSIS PULMONAR IDIOPÁTICA CON INHIBIDORES DE GLUCÓGENO-SINTASA-CINASA 3 FORMA ß. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12083098B2 (https=) |
| EP (1) | EP3793545A4 (https=) |
| JP (2) | JP7471660B2 (https=) |
| KR (1) | KR20210038429A (https=) |
| CN (1) | CN112437663A (https=) |
| AU (1) | AU2019271285B2 (https=) |
| BR (1) | BR112020023422A2 (https=) |
| CA (1) | CA3100381A1 (https=) |
| IL (1) | IL278761B2 (https=) |
| MX (1) | MX2020012331A (https=) |
| WO (1) | WO2019222483A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020415440A1 (en) * | 2019-12-26 | 2022-08-04 | Actuate Therapeutics, Inc. | Compounds for the treatment of myelofibrosis |
| US20250325517A1 (en) * | 2022-06-27 | 2025-10-23 | Actuate Therapeutics, Inc. | Oral dosage forms of elraglusib |
| CN117981712B (zh) * | 2023-07-24 | 2025-02-28 | 南京鼓楼医院 | 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2622987C (en) | 2005-09-20 | 2018-02-27 | New York University | Method of treating pulmonary disease with interferons |
| CA2673368C (en) | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| JP6021117B2 (ja) | 2011-01-31 | 2016-11-02 | ジェノア ファーマシューティカルズ，インク． | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 |
| KR101862291B1 (ko) * | 2011-04-12 | 2018-05-29 | 모레 매트릭스 인코포레이티드 | 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법 |
| US20160375006A1 (en) | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| WO2014165851A1 (en) | 2013-04-05 | 2014-10-09 | The Children's Hospital Of Philadelphia | Transient up-regulation of myc in b-cell lymphomas |
| JP6799201B2 (ja) | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク． | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| JP6534098B2 (ja) | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| EP3665176B1 (en) * | 2017-08-11 | 2024-01-24 | Actuate Therapeutics Inc. | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione |
| PL3697794T3 (pl) * | 2017-10-16 | 2026-04-07 | Actuate Therapeutics Inc. | Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu |
-
2019
- 2019-05-16 WO PCT/US2019/032639 patent/WO2019222483A1/en not_active Ceased
- 2019-05-16 MX MX2020012331A patent/MX2020012331A/es unknown
- 2019-05-16 IL IL278761A patent/IL278761B2/en unknown
- 2019-05-16 CA CA3100381A patent/CA3100381A1/en active Pending
- 2019-05-16 CN CN201980041162.0A patent/CN112437663A/zh active Pending
- 2019-05-16 EP EP19803888.7A patent/EP3793545A4/en not_active Withdrawn
- 2019-05-16 JP JP2021514939A patent/JP7471660B2/ja active Active
- 2019-05-16 AU AU2019271285A patent/AU2019271285B2/en active Active
- 2019-05-16 KR KR1020207035908A patent/KR20210038429A/ko not_active Ceased
- 2019-05-16 BR BR112020023422-2A patent/BR112020023422A2/pt unknown
- 2019-05-16 US US17/056,238 patent/US12083098B2/en active Active
-
2024
- 2024-02-16 JP JP2024021588A patent/JP2024069221A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112437663A (zh) | 2021-03-02 |
| JP7471660B2 (ja) | 2024-04-22 |
| US12083098B2 (en) | 2024-09-10 |
| JP2024069221A (ja) | 2024-05-21 |
| US20210212988A1 (en) | 2021-07-15 |
| EP3793545A4 (en) | 2022-04-06 |
| KR20210038429A (ko) | 2021-04-07 |
| IL278761A (en) | 2021-01-31 |
| WO2019222483A1 (en) | 2019-11-21 |
| AU2019271285B2 (en) | 2024-10-03 |
| CA3100381A1 (en) | 2019-11-21 |
| EP3793545A1 (en) | 2021-03-24 |
| AU2019271285A1 (en) | 2020-12-03 |
| IL278761B1 (en) | 2024-11-01 |
| BR112020023422A2 (pt) | 2021-02-17 |
| IL278761B2 (en) | 2025-03-01 |
| JP2021523951A (ja) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551494A1 (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| TN2019000010A1 (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors | |
| PH12019501350B1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MY199968A (en) | Formulations of an lsd1 inhibitor | |
| SA519401970B1 (ar) | مثبطات حلقية غير متجانسة لناقل مونوكربوكسيلات 4 | |
| ZA202004023B (en) | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| TN2016000458A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer. | |
| EA033284B1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| MX2020012331A (es) | TRATAMIENTO DE FIBROSIS PULMONAR IDIOPÁTICA CON INHIBIDORES DE GLUCÓGENO-SINTASA-CINASA 3 FORMA ß. | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| CY1122587T1 (el) | 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης | |
| TW201613932A (en) | Organic compounds | |
| MX2021008712A (es) | Derivados heterociclicos. | |
| MX2017003466A (es) | Inhibidores de histona desmetilasa. | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| IL288924A (en) | Casein kinase 1 inhibitors for use in the treatment of diseases associated with the expression of dux4 such as muscular dystrophy and cancer | |
| MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. |